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Abstract
Background: Common mental disorders, such as depression, anxiety disorder, and adjustment disorder, have
emerged as a major public and occupational health problem in many countries. These disorders can have severe
consequences such as absenteeism and work disability. Different interventions have been developed to improve
the return-to-work of employees with common mental disorders, but still a large proportion of employees
experiences health and work problems after their return-to-work. For this reason, the SHARP-at work intervention is
developed to prevent a relapse of sickness absence among employees who have returned to work after a period
of sickness absence because of common mental disorders. We aim to evaluate the effectiveness, cost-benefit and
process of the intervention compared to care as usual.
Methods/Design: The study is designed as a cluster-randomised controlled trial with randomisation at the level of
the occupational physician. Employees who have returned to work after a period of sickness absence because of a
common mental disorder are included in the study. Employees in the intervention group will receive the SHARP-at
work intervention. The intervention focusses on active guidance of employees by occupational physicians during
the first weeks of work after sickness absence. Employees in the control group will receive care as usual. Outcomes
will be assessed at baseline and at 3, 6, and 12 months follow-up. The primary outcome is cumulative recurrent
sickness absence days. Secondary outcome measures are mental health, work functioning, and coping. Adherence
to the protocol, communication between stakeholders, and satisfaction with the treatment are the process
measures assessed in both study groups. Cost-benefit is calculated from a societal perspective. Finally, prognostic
factors for a relapse of sickness absence are investigated.
Discussion: This study goes beyond return-to-work by focussing on the prevention of recurrent sickness absence.
The study incorporates not only outcomes on sickness absence and mental health but also on health-related work
functioning. The results of this study can contribute to a further development of practice guidelines and the
promotion of sustainable work participation.
Trial registration: NTR1963
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Common mental disorders (CMDs), such as depression,
anxiety disorder, and adjustment disorder, have emerged
as a major public and occupational health problem in
many countries [1]. Several studies have found a rela-
tionship between CMDs and long term sickness absence
and work disability [2-7]. In the Netherlands, about one
in every three new work disability benefit recipients is
disabled for work because of mental health problems
[8,9]. The increase in sickness absence and work disabil-
ity because of CMDs has serious negative economical
consequences calling for preventive action [3,5,7,10,11].
Recently, attention is also given to the at-work decre-
ments in performance because of CMDs, which seems
to be even more costly than absenteeism [1,6,12-15]. In
their review, Lerner and Henke show that depression is
significantly associated with a reduction of job perfor-
mance and productivity; it was demonstrated that
employees with a significant improvement in depression
still have more trouble with performing well compared
to their healthy colleagues [6]. These findings emphasize
the importance of interventions aiming at employees
with CMDs who are at work. Yet, most interventions
for employees with mental health problems are curative
and focus on reintegration [1 6 - 2 0 ] .N oi n t e r v e n t i o n s
exist which aim at providing support after return-to-
work although it is known that employees who return
to work often are not fully recovered from their initial
complaints [18-20]. Moreover, research in the Nether-
lands showed that one out of five employees who have
returned to work after a sickness absence period
because of a CMD experiences a relapse of sickness
absence due to CMDs (Koopmans et al., submitted for
publication). For these reasons, we have developed an
intervention aiming at the prevention of a relapse of
sickness absence among employees who have (partially/
fully) returned to work after a period of sickness
absence because of a CMD.
The intervention is called “SHARP-at work”.S H A R P
is an acronym for Stimulating Healthy participation And
Relapse Prevention. The intervention is based on the
guideline “Management of mental health problems of
workers by occupational physicians” of the Netherlands
Society of Occupational Medicine. This evidence-based
guideline, developed in 2000 and revised in 2007, is
introduced to facilitate the return-to-work of employees
on sickness absence because of mental health problems
[21,22]. The goal of the guideline is to activate the
employee when stagnation occurs in the process of pro-
blem identification, problem solving, and implementa-
tion of solutions regarding issues that caused sickness
absence and factors that hinder return-to-work. By this,
employees learn to control their own recovery. The
guideline has shown to be effective in reducing the
number of employees who are on long-term sickness
absence because of CMDs [18,23,24].
The SHARP-at work intervention is developed to
improve problem solving strategies regarding problems
or opportunities at work for employees who have
returned to work. Successful implementation of solu-
tions is stimulated by guiding employees in involving
their line manager (i.e. the supervisor). This intervention
will be implemented by the occupational physicians
(OPs) of the employees. The goal of the intervention is
the prevention of a relapse of sickness absence and
improving mental health and work functioning.
Given the serious consequences of CMDs for the indi-
vidual employee and the high social and economic costs
for the workplace, the employer, the health system, and
society, the promotion of sustainable work participation
among employees with CMDs is very important. There-
fore, the primary aim of this study is to evaluate the
effectiveness of the SHARP-at work intervention com-
pared to care as usual (CAU) in preventing a relapse of
sickness absence among employees who have returned
to work after a period of sickness absence because of a
CMD. We hypothesise that employees who return to
work, after sickness absence because of a CMD, and
undergo the SHARP-at work intervention will have less
recurrent sickness absence days compared to employees
who receive CAU. Secondary aims are to improve men-
tal health and work functioning and to stimulate better
coping mechanisms. In addition, the cost-benefit of the
intervention will be examined. Along with these evalua-
tions, we will conduct a process evaluation among
employees, OPs, and line managers. Finally, prognostic
factors for a relapse of sickness absence will be investi-
gated. To our knowledge, this is the first study focussing
on guiding employees at work after they have returned
to work because of a period of sickness absence due to
CMDs.
Methods/Design
The CONSORT statement and the extension for cluster
randomised trials is used to describe the design of the
study [25,26].
Study context
In the Netherlands, both the employer and the employee
are responsible for return-to-work. According to the
Dutch Gate Keeper Act, the employer has a two-year
obligation to pay an employee on sickness absence.
After this period, the employee can apply for work dis-
ability benefit. During the first two years of sickness
absence, the employer and the employee have to make
all efforts possible to realise a return-to-work for the
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contract an occupational physician (OP). The employee
has to visit the OP when being on sickness absence.
OPs treat employees according to guidelines. For CMDs,
the evidence-based guideline of the Netherlands Society
of Occupational Medicine is used to support employees
on sickness absence because of mental health problems
[21,22]. The OP and the employee should be meeting
each other regularly as long as the employee has not
fully returned to work. After full return-to-work, at least
one meeting should take place to focus on relapse pre-
vention. In practice, OPs do not seem to act upon this
last step of the guideline (Rebergen et al., submitted for
publication).
Study design
The study is designed as a two-armed cluster-rando-
mised controlled trial for the prevention of a relapse of
sickness absence by the SHARP-at work intervention
compared to CAU (Figure 1). The study is conducted
among employees who have returned to work after a
period of sickness absence because of a CMD. Randomi-
sation occurs at the level of the OP because employees
can not be randomly assigned to OPs and OPs can not
be expected to provide both guidance according to the
SHARP-at work intervention and CAU. OPs, who have
given their consent for participation, are randomised in
the intervention or control group. OPs in the interven-
tion group receive training in the SHARP-at work inter-
vention. OPs in the control condition do not receive
this training until the end of the study period and pro-
vide CAU.
Employees will be included from December 2009 to
December 2010. OPs will invite an employee to parti-
cipate in the study if the employee is diagnosed with
a CMD at the start of the sickness absence period
Recruitment of OPs by researchers 
OPs randomly allocated to intervention or 
control group 
Training in intervention  No training 
Recruitment of employees by OPs  Recruitment of employees by OPs 
Informed consent & baseline 
questionnaire 
Informed consent & baseline 
questionnaire 
Intervention  Care as usual 
Follow-up questionnaires at 3, 6, and 12 
months 
Follow-up questionnaires at 3, 6, and 12 
months 
Figure 1 Study design.
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OP trained in the intervention will receive the inter-
vention. Employees who are treated by an OP in the
control group will receive CAU. Regardless of the
treatment group, employees still have the possibility
to be treated simultaneously by other health care
workers.
The Medical Ethical Board of the University Medical
C e n t e rG r o n i n g e nh a sg i v e na p p r o v a lf o rt h es t u d y
design, the research protocol, questionnaires, informa-
tion letters, and the informed consent. Employees can
participate voluntarily in this study. They are informed
that they can leave the study at any time without conse-
quences. All employees sign an informed consent. If an
employee drops out, care will be continued.
Recruitment of occupational physicians
Recruitment of OPs takes place in collaboration with
ArboNed, one of the largest Occupational Health Ser-
vices (OHS) in the Netherlands. OPs participating in
this study are employed at this OHS and are affiliated
with companies of different sizes, in different sectors
and in different parts of the Netherlands. Company size
ranges from less than five employees up to more than a
1000 employees in different sectors, for instance indus-
try, education, health care, and customer services. All
regions in the Netherlands, except the south, are partici-
pating in the study. OPs are excluded when they: 1.
have an upcoming retirement, resignation, sabbatical, or
pregnancy leave, or 2. are unable to use the internet
and/or email.
Recruitment of participants
Inclusion criteria
Employees participating in the study are between 18
and 63 years old and employed in a paid job. Further-
more, they have: 1. a diagnosis of a CMD given by their
OP at the start of the sickness absence period, 2. a per-
iod of sickness absence due to a CMD of at least two
weeks, and 3. a planned return-to-work within two
weeks.
Exclusion criteria
Employees are excluded when: 1. the present sickness
absence spell has been longer than 12 months, 2. they
have had a period of sickness absence due to a CMD
three months prior to the present sickness absence
spell, 3. they have severe mental disorders, like psychotic
disorders, bipolar disorder, or post-traumatic stress dis-
order, 4. they have somatic complaints or disorders that
have a predominant influence on work disability, 5. they
are pregnant or have an upcoming retirement, resigna-
tion, or layoff, and 6. they are unable to speak, read,
write, or understand the Dutch language.
Procedure
Employees are recruited by the OPs participating in the
study. The OP checks all inclusion and exclusion cri-
t e r i a .T h ed i a g n o s i so faC M Dh a sb e e nm a d eb yt h e
OP at the start of the sickness absence period. OPs are
trained in diagnosing mental disorders and use a nation-
wide coding system, Classification of Diseases (in Dutch:
CAS) [27], based on the International Classification of
Diseases [28].
If the employee is interested to participate in the
study, the OP asks whether contact information of the
employee can be given to the researcher (IA) and hands
over an information folder about the study. After the
employee has received the information and has given
approval for the researcher to make contact, the OP
gives the contact information to the researcher. The
researcher contacts the employee and asks if the
employee would like to participate in the study. If the
employee is willing to participate, informed consent and
the baseline questionnaire (electronic or paper version)
are send to the employee with a postage paid envelope.
When the informed consent and the baseline ques-
tionnaire are filled in and returned to the researcher,
OPs in the intervention group are informed that the
intervention can be started. OPs in the control group
keep on treating their employees according to CAU.
Follow-up questionnaires are send to the employee at 3,
6, and 12 months. At these points in time, administra-
tive data on cumulative sickness absence days are also
collected by means of the registry system of the OHS.
Intervention
Training of occupational physicians in the intervention
group
OPs receive a two-day training in the SHARP-at work
intervention. Training is provided by experienced trai-
ners in occupational health interventions.
Treatment of participants in the intervention group
The intervention consists of five steps the employee has
to undertake when return-to-work is started. The OP
monitors that the employee follows these steps and uses
interventions to activate the employee when needed.
The five steps are delineated below.
1. Make an inventory of problems and/or opportu-
nities encountered at work
2. Brainstorm on solutions
3. Write down the solutions and the support needed
and assess the applicability
4. Discuss the solutions with the line manager and
make an action plan
5. Evaluate the action plan and the implementation
of solutions
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write down and structure the process. In general, the
OP will counsel on the process level. (S)he does not
discuss the content of problems and solutions but chal-
lenges the employee to reflect on the relative serious-
ness of problems and the feasibility of solutions. This
can be done by asking questions that stimulate the
employee to think about possible perspectives. This
form of guidance is related to Socratic questioning.
The intervention differs from the guideline of the
Netherlands Society of Occupational Medicine by the
emphasis on problems and possibilities encountered at
work when an employee has already returned to work.
Care as usual
Training of occupational physicians in the control group
All OPs participating in the study are trained in the
guideline of the Netherlands Society of Occupational
Medicine. There is no additional training of OPs in the
control group as part of this study. At the end of the
study period these OPs will be trained in the SHARP-at
work intervention if it proves to be effective.
Treatment of participants in the control group
CAU is delivered according to the evidence-based guide-
line of the Netherlands Society of Occupational Medi-
cine [21,22]. CAU comprises guidance in regaining
control and activating problem solving when the
employee is still on sickness absence and at least one
consultation session after return-to-work, addressing
relapse prevention.
Sample size
For the power calculation, recurrent sickness absence
days are considered the primary outcome measure. To
calculate the sample size, administrative data from the
sickness absence registry of the OHS was used. From
2001 to 2007, recurrent sickness absence days among
employees, who had returned to work after a period of
sickness absence because of CMDs, were registered. For
the power calculation, only recurrent sickness absence
days of the first recurrence episode until 1 year later
were used to approximate the 1 year follow-up of the
present study (N = 4443). The variance in recurrent
sickness absence days at the level of the OP was taken
into account.
During the above-mentioned period, the mean days of
recurrent sickness absence was 68.5 (standard deviation
is 119.6). The target of the present study is to reduce
the recurrent sickness absence days with 20%, i.e. an
average of 12.7 recurrent sickness absence days per
employee per year. The OPs in this OHS’s dataset were
randomly divided into two groups. One group was
called “the intervention group” from which 20% of the
recurrent sickness absence days was subtracted to create
the difference between the intervention and control
group and to calculate an effect size.
For a decrease of 12.7 recurrent sickness absence days
per employee during 1 year at alpha = 0.05 and ICC =
0.05, 50 OPs, each providing five employees, need to be
included in each group (the intervention and control
group) [29]. The five employees must be viewed as the
average number per OP. For this multilevel power cal-
culation, an effect size of 0.18 was taken into account.
This effect size was calculated by using a logtransforma-
tion on the data to create a normal distribution and
subsequently by dividing the difference in mean days of
recurrent sickness absence between the intervention and
control group (difference is 0.25) by the standard devia-
tion (standard deviation of difference is 1.4). To include
the effect size in the multilevel power calculation, it had
to be transformed to a correlation coefficient, which
resulted in a correlation of 0.09 [30].
The collaborating OHS serves approximately one mil-
lion insured employees. A total of 350 OPs is working
for this OHS and each OP serves around 2500 to 3000
employees. Of these employees it is estimated that 1.3%
(30% of the national sickness absence rate among Dutch
employees of 4.3%) will be on sickness absence because
of a CMD during a 1 year period [31]. Therefore, an OP
will see around 32 to 39 employees per year who are
absent because of CMDs. Following this, the source
population of the OHS is large enough to recruit the
required number of OPs and employees according to
the sample size calculation.
Randomisation and treatment allocation
Employees can not be randomly assigned to OPs trained
in the intervention or OPs not trained in the interven-
tion because the OPs and employees are bound to each
other by the company. It is also impossible to train all
OPs and to let them randomly apply the intervention or
CAU to employees because of the risk of contamination.
Therefore, randomisation occurs at the level of the OP.
OPs who have given their consent to participate in the
study are randomly assigned to the intervention group
or the control group. To ensure a good contrast
between these two groups, OPs in the intervention
group are specifically asked not to talk about the inter-
vention with OPs in the control group. Additionally, the
OPs in the intervention group have two feedback meet-
ings to discuss the application of the intervention with
each other.
A computerised random allocation sequence for ran-
domising the OPs is developed by an independent
researcher. When all OPs are recruited, the independent
researcher, who is blind to the identity of the OPs, uses
the allocation sequence to randomise the OPs. After
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the independent researcher informs the researchers
about the allocation of the OPs. The allocation of
employees follows from the allocation of their OP.
Employees with an OP in the intervention group are
automatically allocated to the intervention group and
employees with an OP in the control group are automa-
tically allocated to the control group.
Blinding
Validity can be threatened if employees in the interven-
tion and control group would know about the other
group. Because this study is a pre-randomised trial, in
which the employees are already randomised before
informed consent is given, different information about
the study can be provided to the intervention and con-
trol group [32]. To ensure that employees are not aware
and stay unaware of the two study conditions, the OPs
are requested not to talk about this with the employees.
Whereas employees are blinded for treatment allocation,
blinding of allocation for OPs is not possible because
they will know if they are trained in the intervention or
not.
Primary outcome
The primary outcome measure is a relapse of sickness
absence, measured as cumulative recurrent sickness
absence days. A relapse is defined as a 30% decrease in
working days per week or a decrease of at least one day
per week because of sickness absence. Recurrent sick-
ness absence days are operationalised as days of sickness
absence among employees who have worked a steady
amount of days during the first two weeks after they
have returned to work. This information will be
obtained by record linkages with the sickness absence
registry of the OHS and by the employee questionnaires.
Secondary outcomes
Mental health problems
The Four-Dimensional Symptom Questionnaire (4DSQ)
is used to measure symptoms of distress, depression,
anxiety, and somatisation. The 4DSQ is a self-report
questionnaire of 50 items and measures distress, depres-
sion, anxiety, and somatisation. The 4DSQ has been
validated in a primary care and working population
[33,34].
The HADS is a 14-item self-report questionnaire used
to measure depression (7 items) and anxiety (7 items)
[35]. The questionnaire can be used in somatic, psychia-
tric, and primary care patients, as well as in the general
population [36] and in working populations [37]. The
HADS has been validated in different groups of Dutch
subjects [38].
Work functioning
Work functioning is measured by the Work Role Func-
tioning Questionnaire (WRFQ) [39,40]. The question-
naire has been cross-culturally adapted and translated
into Dutch and pre-tested in a working population
(Abma et al., submitted for publication). Results of the
pre-test showed that the cross-cultural adaptation was
successful. The WRFQ measures the perceived difficul-
ties in meeting work demands among employees given
their physical health or emotional problems. The WRFQ
consists of 27 items divided into five subdomains: 1.
work scheduling demands, 2. output demands, 3. physi-
cal demands, 4. mental demands, and 5. social demands.
Coping behaviour
Coping behaviour is measured by the 19-item version of
the Utrecht Coping List (UCL) which assesses coping
styles [41]. The questionnaire consists of the following
five (coping style) scales: 1. active problem-focussing, 2.
seeking social support, 3. palliative reaction pattern, 4.
avoidance behaviour, and 5. expression of emotions.
Economic evaluation measures
Along with the sickness absence data from the OHS’s
registry system, administrative data of the OHS on con-
sultations of the employee with the OP and company
welfare workers is collected. Furthermore, the Trimbos/
iMTA questionnaire for Costs associated with Psychia-
tric Illness (Tic-P), a validated Dutch questionnaire, is
used to measure medical consumption and at-work
decrements in performance [42]. Finally, an extra item
on out-of-pocket costs is added to the Tic-P to calculate
medical expenses that are not covered by health
insurance.
Process evaluation measures
A process evaluation is conducted to examine a) the
appraisals, attitudes, and activities of OPs, employees,
and line managers in the intervention and control group
during the treatment period and b) whether OPs adhere
to their protocol. OPs who are trained in the interven-
tion, receive a questionnaire before and after the train-
ing to examine the quality of the training and the skills
and attitudes of the OPs. For the intervention group, a
questionnaire is developed for the OP and the employee
at baseline. These questionnaires contain items on readi-
ness for change concerning the intervention. At 3-
months follow-up, the employees and the OPs in both
the intervention and control group receive a question-
naire about the process of treatment during the first
three months of return-to-work. The questions elaborate
on what was discussed during the consultations,
whether assignments were given, which assignments
were made, satisfaction with the treatment, and
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manager. For the intervention group, a questionnaire is
also developed for the line manager. The line manager
receives a questionnaire on readiness for change before
a meeting takes place with the employee as part of the
intervention. At 3-months follow-up, the line manager
receives a second questionnaire with the same questions
as the questionnaires at 3 months for the employee and
the OP.
Prognostic measures
Research on prognostic variables for a relapse of sick-
ness absence has only been conducted in a few studies.
For this reason, a range of variables is included in this
study to investigate prognostic factors for a relapse of
sickness absence. At baseline, the following variables are
measured: personal characteristics (e.g. age, gender,
marital status, educational level, and physical health),
job characteristics (e.g. tenure, size of the company, sec-
tor, profession, contract type, number of contract hours
before and after sickness absence, and work accommo-
dations after return-to-work), and psychosocial work
characteristics (job demands, decision latitude, social
support [43,44], job insecurity, conflicts, emotional load
[45], work engagement [46], and expectancy to stay-at-
work).
Statistical analyses
Due to the multilevel design of the study (i.e. employees
are nested in OPs), multilevel regression analyses will be
performed according to the intention-to-treat principle.
Per protocol analyses will be conducted to explore if
deviations from the protocol have caused bias. Descrip-
tive statistics will be used to measure differences in
baseline characteristics between the intervention and
control group. In case of significant differences, these
will be controlled for in the effect evaluations.
Effect evaluation
The primary outcome variable “cumulative recurrent
sickness absence days during follow-up” will be com-
pared between the intervention and control group in the
multilevel regression analyses. Time until a relapse of
sickness absence will be examined by using Cox propor-
tional hazard analysis to estimate hazard ratio’sf o ra
relapse and the 95% confidence interval. In case no soft-
ware is available to conduct these analyses in a multile-
vel structure, cluster level survival analyses will be
conducted with means for each cluster. In these ana-
lyses, cluster size will be introduced as a weighting fac-
tor. To investigate differences between the intervention
and control group in changes (improvement) on all sec-
ondary outcomes, multilevel longitudinal analysis will be
used. Pre-planned subgroup analyses on type of CMD,
line manager participation in the study, size of the
company, perceived decision latitude, type of work, and
expectancy to stay-at-work will be conducted.
Economic evaluation
The economic evaluation will be performed as a cost-
benefit analysis from a societal perspective. For this eva-
luation, the primary outcome measure, i.e. the number
of recurrent sickness absence days after return-to-work,
will be expressed in monetary terms. The time window
will be from return-to-work until 1 year follow-up. Dis-
counting will not be applied.
Both direct and indirect costs will be measured and
valued. Costs of the intervention will be calculated by
using the hourly wages of OPs. All contacts between the
OP and the employee will be registered. The costs of
health care consumption outside the intervention will be
calculated by using tariffs of Dutch Guideline prices [47]
based on information collected by the Tic-P question-
naire [42]. Out-of-pocket costs made by the employees
in relation to their condition will also be included. The
indirect costs of production losses due to sickness
absence and presenteeism will be calculated by using
the Friction costs method [48,49] according to the
Dutch guidelines for economic evaluation [47].
Discussion
This study is designed to investigate if employees, who
have returned to work after a period of sickness absence
because of a CMD, benefit from extra support during
their first weeks of return-to-work. Effectiveness ana-
lyses will be performed to examine if the SHARP-at
work intervention is successful in reducing recurrent
sickness absence days compared to CAU. A cost-benefit
analysis will be conducted to evaluate if the intervention
is efficient, e.g. if better results are not at the expense of
higher costs. Furthermore, the process of the interven-
tion will be evaluated by inquiring employees, OPs, and
line managers on adherence to the protocol and satisfac-
tion with the treatment. Finally, prognostic factors for a
relapse of sickness absence will be investigated.
Methodological considerations
This study design has important strengths. First of all,
the cluster-randomisation diminishes the risk of con-
tamination of employees participating in the study. OPs
are randomised in the intervention or control group, i.e.
they will only treat employees, participating in the
study, according to the SHARP-at work intervention or
CAU. Furthermore, OPs in the intervention and control
group work for different companies or for different
departments of big companies. Hence, it is unlikely that
employees in the intervention group will get in contact
with employees in the control group. Additionally, the
pre-randomisation in the cluster design makes it possi-
ble to blind employees for the study condition. Another
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and subjective data. Recurrent sickness absence days are
not only measured by asking the employees on days of
sickness absence after their return-to-work, but also by
the OHS’s sickness absence registry system. Finally, the
study covers a large geographical area in the Nether-
lands and companies of different sizes and sectors are
included. This will make it possible to generalise the
results to a relatively large working population.
A limitation of the study is the inclusion of participants
by the OPs. The possibility exists that OPs in both study
groups select those employees who have, in their view,
good potential for fast recovery and small chances for a
relapse of sickness absence. Although it has been stressed
to all OPs to invite all employees eligible for the study, we
can not exclude the possibility of bias. Questions to inves-
tigate if participating employees were thought to be more
suitable for the study are included in the process evalua-
tion for OPs. Another possibility for bias to occur is the
selection of employees who have a good relationship with
their OP. Unfortunately, we can not exclude this bias, but
we ask questions in the process evaluation on the relation-
ship between the OP and the employee. Finally, recruiting
500 employees for the study is a challenge. Most studies in
this field have problems with recruiting participants. We
have tried to minimise these problems by embedding this
study in one large OHS. All participating OPs work for
the same OHS and are stimulated to contribute to the
study by this OHS. Moreover, we expect fewer refusals to
participate because OPs invite employees to participate in
the study. The OP has already built a relationship with the
employee which will contribute to a safe environment to
make the choice to participate in the study.
Relevance/impact of results
This study goes beyond return-to-work by focussing on
sustainable work participation after return-to-work. It
incorporates not only outcomes on sickness absence and
mental health but also on health-related work function-
ing. The study has a high societal relevance because
costs for sickness absence could be lowered and a sus-
tainable working life could be facilitated. Furthermore,
OPs and other occupational health professionals may
benefit from the intervention as it could serve as an
extension of the already existing guideline of the Neth-
erlands Society of Occupational Medicine. Results of the
study will become available in 2012.
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